Millington Financial Advisors LLC Takes $778,000 Position in Sanofi (NASDAQ:SNY)

Financial Advisors


Millington Financial Advisors LLC purchased new shares of Sanofi (NASDAQ:SNY – Get Rating) in the fourth quarter, according to its latest Form 13F filed with the SEC. The fund purchased 16,058 shares of the company stock valued at approximately $778,000.

Other big investors have increased or decreased their stakes in the company recently. Boston Partners increased his stake in Sanofi by 48.9% in the third quarter. Boston Partners now owns 17,723,199 shares worth $677,539,000 after acquiring an additional 5,822,516 shares during the previous quarter. Arrowstreet Capital Limited Partnership increased its stake in Sanofi by 276.1% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 of his shares worth $172,611,000 after acquiring an additional 2,468,271 of his shares during the previous quarter. MUFG Securities EMEA plc acquired his $96,275,000 worth of new positions in Sanofi shares in the fourth quarter. Sofinnova Investments Inc. increased his Sanofi holding by 348.1% in the third quarter. Sofinnova Investments Inc. now owns 1,264,546 shares worth $48,078,000 after purchasing an additional 982,346 of his shares last quarter. Finally, Natixis Advisors LP increased its Sanofi holding by 93.0% in the fourth quarter. Natixis Advisors LP now owns 1,687,635 shares worth $81,732,000 after purchasing an additional 813,365 shares last quarter. 10.04% of the shares are owned by institutional investors and hedge funds.

sanofi stock performance

NASDAQ SNY shares climbed $1.05 in intraday trading on Friday to reach $55.78. The company’s average trading volume was 1,965,823 shares for him, while the company’s trading volume was 410,898 shares. The company has a debt to equity ratio of 0.20, a current ratio of 1.42 and a quick ratio of 1.05. His 50-day simple moving average for this business is $54.83 and his 200-day simple moving average is $50.24. His 12-month low on Sanofi is $36.91 and his 12-month high is $57.82. The company has a market capitalization of $140.66 billion, a P/E ratio of 20.01, a PEG ratio of 1.76 and a beta of 0.57.

Sanofi (NASDAQ:SNY – Get Rating) last reported earnings on Thursday, April 27. The company reported his earnings per share of $1.16 for the quarter, beating consensus expectations of $1.10 for him by $0.06. Sanofi’s net profit margin was 15.41% and return on equity was 28.45%. The business generated $10.97 billion in revenue for the quarter, compared with analyst estimates of $11.60 billion. As a group, analysts expect Sanofi to post his earnings per share of 4.49 for the current financial year.

Sanofi cuts dividend

The business recently announced an annual dividend payable on Friday, June 23rd. Investors of record on Wednesday, May 31 will receive a dividend of $1.377. This represents a dividend yield of 2.94%. The ex-dividend date is Tuesday, May 30. Sanofi’s dividend payout ratio is currently 45.16%.

Wall Street analyst opinion

A number of brokerage firms have recently issued reports on SNY. In his March 27 report, Barclays upgraded Sanofi’s shares from an ‘equal weight’ rating to an ‘overweight’ rating. Deutsche Bank Aktiengesellschaft downgraded Sanofi’s shares from ‘hold’ to ‘sell’ in a report on Friday, April 28. StockNews.com upgraded Sanofi’s stock from a “buy” rating to a “strong buy” rating in a report on Monday, March 27. Finally, Argus raised its price target on Sanofi stock from $55.00 to $60.00, giving it a Buy rating in its report on Monday, March 27. One Equity Researcher gave stocks a sell rating, three gave hold ratings, six gave buy ratings, and one analyst assigned a strong buy rating to stocks. According to MarketBeat.com, the company’s consensus rating is “moderate buy” with an average price target of $94.50.

About Sanofi

(get rating)

Sanofi is engaged in the research, manufacture and marketing of pharmaceutical products. It operates through its Pharmaceuticals, Consumer Healthcare and Vaccines business segments. The Pharmaceuticals segment consists of the commercial activities of the following global franchises: Specialty Care, Diabetes and Cardiovascular, Established Prescription and Generic Medicines, and Research, Development and Manufacturing Activities.

Related item

Sanofi (NASDAQ:SNY) Quarterly Institutional Ownership

This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.

Listen to this before considering Sanofi.

MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Sanofi wasn’t on the list. .

Sanofi currently holds a ‘moderate buy’ rating among analysts, although top-rated analysts believe these five stocks are better buys.

See 5 stocks here

7 shares to buy and keep forever



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *